Coronavirus Vaccine Human Trials
--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

Coronavirus Vaccine Human Trials – Chinese COVID-19 Vaccine

China approves human trials of potential coronavirus vaccine

In a race to develop a shot against the coronavirus pandemic, which has taken the lives of more than 7,000 people worldwide, China has approved the researchers to start human safety tests of an experimental coronavirus vaccine.

As of March 18, 2020, the COVID-19 has infected around 198,193 people worldwide and the death toll has reached 7,954 deaths with a total of 81,961 recovered patients. The recovery of a patient solely depends on the immunity of the person and the chances are high if the person has no underlying health conditions and is diagnosed early. However, the need for a vaccine is more than ever as the death rate keeps increasing with the virus spreading all over the world.

Starting this week, the scientists at China’s Academy of Military Medical Sciences have received approval to launch early-stage clinical trials of the potential vaccine, according to a report from the ruling Communist Party.

A vaccine developed by the National Institute of Allergy and Infectious Diseases in the US and Moderna, the US biotech firm, had entered clinical trials on Monday, said the scientists in the

United States. A volunteer from the country got the first shot of coronavirus COVID-19 vaccine on Monday.

Between March 16 and December 31, a “Phase 1” test aims to recruit 108 healthy people to examine whether the experimental shot is safe in humans, according to the details in the Chinese clinical trial registration database.

The database showed that the CanSino Biologics, the Hong Kong-listed biotech firm and the Academy of Military Medical Sciences of China will be conducting the trial.

However, the experts at the World Health Organization said that until the middle of next year, they do not expect any fully tested and approved vaccine to reach the market.

Source